M.D. Sass LLC Has $93.84 Million Stock Holdings in Henry Schein, Inc. $HSIC

M.D. Sass LLC boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.9% in the first quarter, HoldingsChannel reports. The fund owned 1,273,316 shares of the company’s stock after purchasing an additional 35,443 shares during the quarter. Henry Schein makes up 7.1% of M.D. Sass LLC’s portfolio, making the stock its largest position. M.D. Sass LLC’s holdings in Henry Schein were worth $93,843,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Compound Planning Inc. boosted its stake in Henry Schein by 15.0% in the first quarter. Compound Planning Inc. now owns 4,190 shares of the company’s stock valued at $309,000 after acquiring an additional 546 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Henry Schein by 1,263.1% during the first quarter. Bank of Nova Scotia now owns 116,808 shares of the company’s stock worth $8,609,000 after purchasing an additional 108,239 shares in the last quarter. State of Wyoming increased its position in shares of Henry Schein by 32.9% during the first quarter. State of Wyoming now owns 14,555 shares of the company’s stock worth $1,073,000 after purchasing an additional 3,605 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Henry Schein by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after purchasing an additional 56,687 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Henry Schein by 12.7% during the 1st quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock valued at $97,000 after purchasing an additional 148 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Performance

NASDAQ HSIC opened at $84.53 on Friday. The stock has a 50-day simple moving average of $80.72 and a two-hundred day simple moving average of $77.99. The firm has a market capitalization of $9.63 billion, a P/E ratio of 25.54, a PEG ratio of 1.63 and a beta of 0.81. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.34. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the firm posted $1.15 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Analysts Set New Price Targets

HSIC has been the topic of several research analyst reports. Morgan Stanley restated an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. BMO Capital Markets started coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target for the company. Wall Street Zen downgraded Henry Schein from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Mizuho dropped their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $87.64.

Insiders Place Their Bets

In related news, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.